Shahabi; Vafa

Patent Applications and Registrations

Patent applications and USPTO patent grants for Shahabi; Vafa.The latest application filed is for "compositions and methods comprising klk3 or folh1 antigen".

Company Profile

0.10.19

Shahabi; Vafa - Valley Forge PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and methods comprising KLK3 or FOLH1 antigen Grant 11,446,369 - Paterson , et al. September 20, 2	2022-09-20
Compositions And Methods Comprising Klk3 Or Folh1 Antigen App 20200069785 - PATERSON; Yvonne ; et al.	2020-03-05
Dual delivery system for heterologous antigens Grant 9,650,639 - Maciag , et al. May 16, 2	2017-05-16
Dual delivery system for heterologous antigens Grant 9,644,212 - Maciag , et al. May 9, 2	2017-05-09
Compositions And Methods Comprising Klk3 Or Folh1 Antigen App 20170100469 - PATERSON; Yvonne ; et al.	2017-04-13
Compositions and methods comprising KLK3 or FOLH1 antigen Grant 9,549,973 - Paterson , et al. January 24, 2	2017-01-24
Compositions And Methods For The Treatment Of Her2/neu Over-expressing Tumors App 20160361401 - Shahabi; Vafa ; et al.	2016-12-15
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20150366955 - SHAHABI; VAFA ; et al.	2015-12-24
Compositions And Methods Comprising Klk3 Or Folh1 Antigen App 20150335721 - PATERSON; YVONNE ; et al.	2015-11-26
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20150297702 - SHAHABI; VAFA ; et al.	2015-10-22
Biomarkers For Predicting Clinical Response Of Cancer Patients To Treatment With Immunotherapeutic Agent App 20150299804 - ARTOMOV; Maksym ; et al.	2015-10-22
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20150238584 - SHAHABI; VAFA ; et al.	2015-08-27
Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors Grant 9,084,747 - Shahabi , et al. July 21, 2	2015-07-21
Anti-tumor Antibodies As Predictive Or Prognostic Biomarkers Of Efficacy And Survival In Ipilimumab-treated Patients App 20150118244 - Shahabi; Vafa ; et al.	2015-04-30
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors Grant 9,017,660 - Shahabi , et al. April 28, 2	2015-04-28
Methods For Predicting Gastrointestinal Immune-related Adverse Events (gi-irae) In Patients Treated With Modulation Of The Co-stimulatory Pathway App 20150110779 - Shahabi; Vafa ; et al.	2015-04-23
Compositions and methods comprising KLK3 of FOLH1 antigen Grant 9,012,141 - Paterson , et al. April 21, 2	2015-04-21
Dual Delivery System For Heterologous Antigens App 20140335120 - MACIAG; Paulo ; et al.	2014-11-13
Dual Delivery System For Heterologous Antigens App 20140314708 - Maciag; Paulo ; et al.	2014-10-23
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20140234370 - SHAHABI; Vafa	2014-08-21
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20120014984 - SHAHABI; Vafa	2012-01-19
Live Listeria-based Vaccines For Central Nervous System Therapy App 20110223187 - SHAHABI; Vafa ; et al.	2011-09-15
Compositions And Methods For Prevention Of Escape Mutation In The Treatment Of Her2/neu Over-expressing Tumors App 20110142791 - SHAHABI; VAFA	2011-06-16
Dual Delivery System For Heterologous Antigens App 20110129499 - Maciag; Paulo ; et al.	2011-06-02
Enhancing protein expression App 20090069256 - Smith; Larry R. ; et al.	2009-03-12
Compositions and methods comprising KLK3 of FOLH1 antigen App 20070253976 - Paterson; Yvonne ; et al.	2007-11-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.